Arcus Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcus Biosciences (RCUS).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$37Upside to Avg. PT+101.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$45→$50
Oct 21, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$40→$41
Oct 21, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$43→$49
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 14, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$41
Sep 30, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$43
Sep 16, 2026	TD Cowen	Tara Bancroft	Initiate	Buy	—
Sep 8, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
Aug 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
Jul 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
Jun 4, 2026	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
May 18, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
May 11, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
May 7, 2026	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
Apr 2, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
Mar 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45
Mar 2, 2026	Leerink Partners	Geoffrey Porges	PT Raise	Outperform	$36→$49
Mar 2, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$32
Feb 12, 2026	Wells Fargo	Eva Fortea Verdejo	Downgrade	Overweight→Equal-Weight	$30→$23

Analyst Ratings News

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.

Benzinga Newsdesk

Arcus Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

People Also Watch

People Also Watch

Arcus Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PROTruist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PROWilliam Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PROJP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PROWedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target